Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

sents an increase of $188,000 or 6.8% when compared to product revenue in fiscal 2007 of $2,764,000. Product sales of Klean-Prep(TM) continued to grow in fiscal 2008 and more than offset lower sales of Orthovisc(R) in Canada.

License fees and royalties in fiscal 2008 totaled $639,000 and represent an increase of $127,000 or 24.8% when compared to fiscal 2007. The increase is mainly the result of a milestone payment from the sub-licensing arrangement of the Company's biochip technology to Lumera Corporation. Lumera has now given notice of its termination of the sub-license effective December 19, 2008.

Research and development contract revenue in fiscal 2008 totaled $nil and represents a decrease of $148,000 when compared to fiscal 2007. The Company completed a research and development contract in the third quarter of fiscal 2007 and currently has no plans to contract its research and development services out to third parties, but instead is focusing its resources on the development of two product candidates: L-DOS47 and Topical Interferon Alpha-2b.

Cost of sales in fiscal 2008 and 2007 totaled $1,239,000 and $1,139,000, respectively. As a percentage of product revenues, cost of sales in fiscal 2008 and 2007 were 42.0%, 41.2%, respectively. The Canadian dollar's strength over the last three fiscal years has moderated in fiscal 2008 and was range bound, reflecting slight higher cost of sales.

Research and development expenditures in fiscal 2008 totaled $5,064,000 and represent an increase of $948,000 or 23.0% when compared to fiscal 2007. Both Topical Interferon Alpha-2b and DOS47 reflect an increase of 20.6% and 25.0%, respectively. The increase in DOS47 research and development expenditures reflect advancing preclinical costs in preparation for L-DOS47 pre-IND meetings and a Phase I IND filing to occur sometime before the end of Helix's fiscal fourth quarter ending July 31, 2009. The increase in research and development expenditures relate
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... DANVILLE, Pa. , Aug. 19, 2014 ... C has been nominated for a Centers for Disease ... to addressing a major public health concern. ... Health System, is one of a team of researchers ... (CDC) Charles C. Shepard Science Award for Data Methods ...
(Date:8/19/2014)... 19, 2014 Robin Williams’ passing is ... take on an individual. Symptoms range from slowness ... problems swallowing and severe depression. Parkinson’s disease progressively ... of dopamine producing neurons of the brain. As ... that slowly and progressively gets worse, they look for ...
(Date:8/19/2014)... CSSi, the leader in patient recruitment solutions ... of the company,s Medical and Clinical Advisory Board ("MCAB") ... William E. Gannon, Jr. to the MCAB. ... The MCAB, with Dr. Gannon,s leadership, will help ... set strategic goals for the advancement and development of ...
(Date:8/19/2014)... 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the ... of its Oral Amphotericin B (Oral Amp B) ... conducted by ImmuneCarta®, the immune monitoring business unit ... of Oral Amp B in reactivating latent HIV ... intensive treatment with antiretroviral therapy. ...
Breaking Biology Technology:Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... financial guidance through second quarter of 2009 - ... - Conference ... BRANFORD, Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRGN ), today ... the three month period ended September 30, 2008, CuraGen,utilized $3.6 million ...
... and terms of his settlement with the SEC. Case No. 2:08-cv-2252-GEB-DAD. ... ... Rancho Cordova, California Corporation, was formed in 2005 to develop and ... cancer, particularly diseases related to chromosomal telomere shortening. The Company worked ...
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced ... Company,s request for an,extension until December 3, 2008 ... capitalization requirement of $35 million or the alternative,requirement ... to remain,listed. There can be no assurance that ...
Cached Biology Technology:CuraGen Reports Third Quarter 2008 Financial Results 2CuraGen Reports Third Quarter 2008 Financial Results 3CuraGen Reports Third Quarter 2008 Financial Results 4CuraGen Reports Third Quarter 2008 Financial Results 5CuraGen Reports Third Quarter 2008 Financial Results 6Former Telomolecular CEO Clarifies SEC Settlement 2Former Telomolecular CEO Clarifies SEC Settlement 3Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements 2
(Date:8/20/2014)... August 19, 2014 -- Bay Area Lyme Foundation, which ... simple to cure, applauds new research published in an ... Ticks and Tick-borne Diseases . The findings show ... are active throughout the year, making the threat of ... at California Department of Public Health (CDPH) Vector-borne Disease ...
(Date:8/20/2014)... acral melanomas the rare type of skin cancer that ... from other more common types of skin cancer, according to ... Pigment Cell & Melanoma Research . , Acral melanoma most ... feet, nail-beds and other hairless parts of the skin. Unlike ... UV damage from the sun. , The team, from the ...
(Date:8/20/2014)... seawater signals a relaxing trip to the shore. But ... comes with an environmental hitch. When certain sunblock ingredients ... become toxic to some of the ocean,s tiniest inhabitants, ... animals. Their study appears in the ACS journal ... David Snchez-Quiles point out that other than staying indoors, ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... in Japan may have developed a way to accurately predict ... the standard of care for chronic myeloid leukemia (CML). ... a journal of the American Association for Cancer Research. ... treatment of leukemia when it was approved in 2001. Yet ...
... July 28 BIO-key International, Inc. (OTC Bulletin Board: ... financial results for the second quarter and six month period ... the data presented in this release relative to the same ... fingerprint-based Biometrics Division. The company completed the sale of its ...
... required to smoke "electronic cigarettes" marketed as ... with possible adverse effects on human health, researchers ... The researchers used a smoking machine to compare ... five e-cigarette brands. They examined the vacuum required ...
Cached Biology News:New lab test could identify imatinib resistance 2BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 2BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 3BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 4BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 5BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 6BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results 7Electronic cigarettes require more suction than conventional brands 2Electronic cigarettes require more suction than conventional brands 3Electronic cigarettes require more suction than conventional brands 4